Research Topic

Metformin: Beyond Diabetes

About this Research Topic

In the world of drug repositioning metformin has a prominent place. This anti-diabetic medication which belongs to the family of biguanides has been prescribed for more than 60 years in Europe. Recently, metformin has generated lot of excitement with the discovery of potential therapeutic effects in addition to its antidiabetic properties. In some studies metformin use has been associated with a reduced risk of cancer and cardiovascular disease, findings that are also supported by preclinical studies in cells and experimental models. The keen interest for this drug and its low cost have led clinicians to initiate many trials, with more than 150 registered for cancer or cardiovascular disease therapy and prevention. The revival of metformin encompasses a growing number of pathologies and this Research Topic will address these broad scientific and clinical aspects of metformin action beyond diabetes. As the first line treatment for type 2 diabetes, metformin is one of the top prescribed drugs in the world. It decreases hyperglycemia and thus hyperinsulinemia, in addition to its systemic effects. Metformin inhibits the respiratory chain of the mitochondria, disrupting energy supply in cancer and other cells. These actions may contribute towards the anti-tumoral action of the drug and may also contribute towards the extended lifespan observed in animal models treated with metformin. Metformin has also an impact on pathologies associated with ageing, indeed, several epidemiological and pre-clinical studies have shown that metformin may be beneficial in Alzheimer’s disease, stroke and other degenerative brain diseases. More recent studies have reported metformin-induced changes in gut microbiota that may contribute towards metformin’s benefits on metabolism. Finally, the anti-inflammatory and anti-infectious properties of the drug have reinforced metformin as an attractive candidate for drug repurposing.

This Research Topic collection aims to provide an up-to-date summary of recent advances on metformin biology and clinical studies in nondiabetic pathologies. It will encourage, with no limitations, reviews on: epidemiology and clinical trials, alongside those on preclinical studies of drug mechanism.


Keywords: Metformin, Cancer, Neurodegenerative diseases, Metabolism, Inflammation


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

In the world of drug repositioning metformin has a prominent place. This anti-diabetic medication which belongs to the family of biguanides has been prescribed for more than 60 years in Europe. Recently, metformin has generated lot of excitement with the discovery of potential therapeutic effects in addition to its antidiabetic properties. In some studies metformin use has been associated with a reduced risk of cancer and cardiovascular disease, findings that are also supported by preclinical studies in cells and experimental models. The keen interest for this drug and its low cost have led clinicians to initiate many trials, with more than 150 registered for cancer or cardiovascular disease therapy and prevention. The revival of metformin encompasses a growing number of pathologies and this Research Topic will address these broad scientific and clinical aspects of metformin action beyond diabetes. As the first line treatment for type 2 diabetes, metformin is one of the top prescribed drugs in the world. It decreases hyperglycemia and thus hyperinsulinemia, in addition to its systemic effects. Metformin inhibits the respiratory chain of the mitochondria, disrupting energy supply in cancer and other cells. These actions may contribute towards the anti-tumoral action of the drug and may also contribute towards the extended lifespan observed in animal models treated with metformin. Metformin has also an impact on pathologies associated with ageing, indeed, several epidemiological and pre-clinical studies have shown that metformin may be beneficial in Alzheimer’s disease, stroke and other degenerative brain diseases. More recent studies have reported metformin-induced changes in gut microbiota that may contribute towards metformin’s benefits on metabolism. Finally, the anti-inflammatory and anti-infectious properties of the drug have reinforced metformin as an attractive candidate for drug repurposing.

This Research Topic collection aims to provide an up-to-date summary of recent advances on metformin biology and clinical studies in nondiabetic pathologies. It will encourage, with no limitations, reviews on: epidemiology and clinical trials, alongside those on preclinical studies of drug mechanism.


Keywords: Metformin, Cancer, Neurodegenerative diseases, Metabolism, Inflammation


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

31 January 2018 Abstract
04 April 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

31 January 2018 Abstract
04 April 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top